What is CombiPGS?

CombiPGS is a Preimplantation Genetic screening method offered by CombiMatrix. During the screening process of embryos, CombiPGS detects whole chromosomal duplications and deletions across all chromosomes.

When an entire chromosome is extra or is missing, or a significant portion is deleted or duplicated, malformations or miscarriage often occur. Approximately 1 in 5 clinically recognized pregnancies end in miscarriage, and of early pregnancy losses, approximately 50% have a significant chromosomal abnormality.

CombiPGS is an advanced genetic screening method used to evaluate whether an embryo might have chromosomal abnormalities.

Some of the benefits CombiPGS has to offer is that it can help:

- Increase the chance of a successful pregnancy.
- Reduce the number of IVF cycles
- Lower the likelihood of an abnormal pregancy
- Decrease the risk of a miscarriage by selecting a healthy embryo

About Us

We are a genetic testing laboratory whose mission is to provide specialized genetic tests that make a difference. Our testing services provide patients and physicians with information that can assist in making more informed healthcare decisions.

Understanding Preimplantation Genetic Screening (PGS)

Clinical Insights.

Improved Success.

INVITAE | CombiMatrix

300 Goddard, Suite 100 | Irvine, CA 92618 | T: 800.710.0624

info@combimatrix.com | www.combimatrix.com

INVITAE | CombiMatrix

Is PGS right for you?

Preimplantation Genetic Screening (PGS) helps determine if aneuploidy or other significant chromosomal abnormalities exist that could negatively impact the embryo. The test is performed during in vitro fertilization to ensure that only embryos that have apparently normal chromosomes are selected.*

PGS is of benefit for couples that:

- Have experienced previously failed IVF cycles
- Had recurrent miscarriages
- Had prior pregnancies with chromosomal abnormalities
- Are planning a single-embryo transfer
- Have maternal age of ≥ 35
- Want to decrease the chance of chromosomal abnormalities in their baby

How Is PGS Performed?

The PGS process involves removing a single or multiple cells from a blastocyst or trophectoderm, embryos that are 3-5 days old. The cell(s) is sent to CombiMatrix where advanced microarray technology is used to screen the cell(s) for aneuploidy. Results are generally delivered to the IVF center in time for embryo selection and implantation. Your doctor will review the results with you.

What is Aneuploidy?

Aneuploidy describes a condition where an error in cell division occurred, resulting in missing or duplicated chromosomes. Such errors often cause genetic disorders including birth defects - one of the most common ones being Down Syndrome, Edwards Syndrome and Turner Syndrome.

As the maternal age increases so do the chances for aneuploidy. With Day 3 embryo biopsies, about 2/3 of women under the age of 35 have embryos with aneuploidy; this percentage increases to over 80% for women aged 40 and above.

Using CombiPGS with its comprehensive genetic analysis increases the chances of a successful IVF cycle, providing you with the best chance for a healthy baby.



What is my Patient Responsibility for a Preimplantation Genetic Screening?

Prior to beginning any procedure, CombiMatrix will work with your provider to inform you of your patient responsibility. Payment must be received before testing can be performed..

Additional Questions?

If you still have questions or want to learn more, speak to your doctor, genetic counselor or other healthcare provider.

Additional information is also available on our website at www.combimatrix.com.

** PGS assesses for aneuploidy; it does not detect microdeletions or duplications that cause rare disorders such as DiGeorge Syndrome or Prader-Willi. It also does not detect single gene disorders such as cystic fibrosis.*

CombiMatrix